News | Cardiovascular Business | July 20, 2017

Hospital Readmissions Analysis Across All Ages, Insurance Types Identifies High-Risk Groups

Findings suggest targeted interventions for high-risk groups and select conditions could reduce readmission costs and burden

Hospital Readmissions Analysis Across All Ages, Insurance Types Identifies High-Risk Groups

July 20, 2017 — Clinician-researchers at Beth Israel Deaconess Medical Center (BIDMC) recently published a first-of-its-kind analysis comparing the rates, characteristics and costs of hospital readmissions across all ages and insurance types.

Short-term hospital readmissions – or readmissions within 30 days – are common, costly and a substantial contributor to healthcare utilization. Annual costs of readmissions among patients who receive Medicare account for billions of dollars in national healthcare spending, and those costs are expected to increase over the next decade. While there is research that examines short-term readmissions for patients in the Medicare and Medicaid populations, no analysis existed of readmission rates across the spectrum of all age groups and insurance types.

The study, published in the journal PLOS ONE, found that non-Medicare patients accounted for nearly half of all short-term readmissions, and that psychiatric disease and substance abuse were the most common diagnoses associated with readmission among non-elderly patients, those ages 18 to 64. These findings suggest the importance of developing and implementing proven interventions to reduce psychiatric readmissions regardless of insurance type. Medicaid patients, in particular, were found to have very high rates of short-term readmissions across all age groups.

“As re-hospitalization costs continue to rise, efforts to reduce hospital readmission rates have become a national healthcare priority,” said senior author Robert Yeh, M.D., MSc, MBA, director of the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology at BIDMC. “With this analysis we determined the specific causes of and the cost burdens associated with readmissions for patients of all ages and insurance coverage. We found there is tremendous potential to reduce readmissions by delivering targeted interventions for specific conditions within high-risk groups.”

The researchers evaluated data from the Nationwide Readmissions Database for patients over the age of 18 years old who were hospitalized for any condition and discharged between January 2013 and November 2013. The researchers categorized the patients based on age: 18-44, 45-65 and 65 and older. The data included discharges at more than 2,000 hospitals in 21 states.

The large-scale analysis found that of the more than 12.5 million discharges evaluated, approximately 1.8 million patients were readmitted within 30 days. Medicare patients accounted for 56 percent of all readmissions. Those readmissions translated to total annual hospital costs of $50.7 billion – Medicare readmissions resulting in a cost of $29.6 billion and non-Medicare in a cost over $21 billion in 2013. 

“Our findings show that while Medicare readmissions represent more than half of all hospital readmissions, non-Medicare readmissions are frequent and make up a significant percentage and substantial cost,” said first author Jordan Strom, M.D., research fellow at the Richard A. and Susan F. Smith Center for Outcomes Research in Cardiology at BIDMC.

“We found that readmission among the non-elderly was most often driven by psychiatric and substance abuse problems, compared to the most common reasons for readmission in the elderly, which included pneumonia, heart failure and heart attack,” Strom added.

The topic of hospital readmissions remains a major interest at the federal and state level. Last year, Yeh and colleagues published research which found that after the passage of the Affordable Care Act’s Hospital Readmissions Reduction Program, hospitals that were the lowest performers prior to the law’s enactment went on to improve the most after being penalized financially. Building on that previous work, these latest findings communicate the cost and cause of hospital readmissions and may provide insight as national healthcare legislation is deliberated and changes to Medicaid funding are proposed.

“These findings clearly highlight the significant use of unplanned hospital-based care among younger patients, particularly among the Medicaid population,” said Yeh. “Therefore any changes to Medicaid coverage will require alternative solutions to ensure that the current benefits can continue to be provided without creating financial catastrophe for these patients or the institutions that care for them.” 

In addition to Yeh and Strom, study authors include Daniel Kramer, M.D., MPH; Changyu Shen, Ph.D.; and Elissa Wilker, ScD, all of BIDMC; Yun Wang, Ph.D., Harvard T.H. Chan School of Public Health; Jason Wasfy, M.D., MPhil, Massachusetts General Hospital; and Bruce Landon, M.D., MBA, MSc, Harvard Medical School.

This research was funded by a philanthropic grant from the family of Richard A. and Susan F. Smith. Yeh and Strom are also supported by National Heart, Lung and Blood Institute (R01 HL136708-01 - Yeh, T32 HL007374-37 - Strom).

Dr. Yeh eas an author in a study about "Excluding High-Risk Patients from Public Reporting Linked to Improved PCI Outcomes," and was a speaker at ACC.16 on "Questions Remain on DAPT Prolongation."

For more information: www.journals.plos.org/plosone


Related Content

News | Cardiovascular Business

July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing ...

Home July 29, 2024
Home
News | Cardiovascular Business

July 18, 2024 — Circle Cardiovascular Imaging, a developer of artificial intelligence (AI)-driven cardiovascular imaging ...

Home July 18, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Guidehealth, an artificial intelligence (AI)-enabled healthcare services company, has announced a ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 15, 2024 — Edwards Lifesciences announced it has exercised its option to acquire Innovalve Bio Medical Ltd., an ...

Home July 15, 2024
Home
News | Cardiovascular Business

July 11, 2024 — Medical device company R3 Vascular Inc., developer of novel, best-in-class bioresorbable scaffolds for ...

Home July 11, 2024
Home
News | Cardiovascular Business

July 9, 2024 — Disparities in cardiovascular disease outcomes between urban and rural areas continue to widen, yet ...

Home July 09, 2024
Home
Feature | Cardiovascular Business

The DAIC team wishes you a safe and happy 4th of July!

Home July 04, 2024
Home
News | Cardiovascular Business

July 3, 2024 — Over the past decade, 342 cardiology clinics have been acquired by private equity firms, with over 94% of ...

Home July 03, 2024
Home
Feature | Cardiovascular Business | By Melinda Taschetta-Millane

From FDA approvals to new clinical trials, here is a look at DAIC's top-read content during the month of June: 1 ...

Home July 02, 2024
Home
News | Cardiovascular Business

July 1, 2024 — CVRx, Inc., a commercial-stage medical device company, announced three additions to its senior leadership ...

Home July 01, 2024
Home
Subscribe Now